• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Protagonist Therapeutics Inc (NQ: PTGX )

    32.01 -0.25 (-0.77%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 305,118
    Open 32.69
    Bid (Size) 30.77 (1)
    Ask (Size) 33.13 (1)
    Prev. Close 32.26
    Today's Range 31.93 - 32.95
    52wk Range 13.72 - 35.96
    Shares Outstanding 58,652,133
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
    Via ACCESSWIRE
    The 3 Best Biotech Stocks to Buy in June 2024
    Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. 
    Via InvestorPlace

    Performance

    YTD
    +36.68%
    +36.68%
    1 Month
    +5.26%
    +5.26%
    3 Month
    +14.77%
    +14.77%
    6 Month
    +39.05%
    +39.05%
    1 Year
    +11.34%
    +11.34%

    More News

    Read More
    Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
    Via ACCESSWIRE
    Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
    Via ACCESSWIRE
    PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Via ACCESSWIRE
    Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
    Via ACCESSWIRE
    Protagonist Therapeutics to Participate in Upcoming Investor Conferences
    Via ACCESSWIRE
    Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    Via ACCESSWIRE
    Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
    Via ACCESSWIRE
    Turnstone Biologics Appoints William Waddill to its Board of Directors
    From Turnstone Biologics Corp.
    Via GlobeNewswire
    Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
    Via ACCESSWIRE
    Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
    Via ACCESSWIRE
    New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
    Via ACCESSWIRE
    Protagonist Therapeutics Reports Granting of Inducement Awards
    Via ACCESSWIRE
    New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
    Via ACCESSWIRE
    Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
    Via ACCESSWIRE
    Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024
    Via ACCESSWIRE
    Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
    Via ACCESSWIRE
    Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
    Via ACCESSWIRE
    Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals
    Via ACCESSWIRE
    Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib
    Via ACCESSWIRE
    Protagonist Therapeutics Reports Granting of Inducement Awards
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.